Shots:
The companies collaborated for a P-I dose escalation trial evaluating TILT-123 in combination with Keytruda (pembrolizumab) in 12 to 24 patients with immune checkpoint inhibitor refractory NSCLC
This recent trial adds to the business’ developing data on the utilization of its oncolytic immunotherapy candidate TILT-123, which is presently being tested for multiple other indications and has shown promising results in terms of its usability when administered intravenously
TILT’s TILT-123 is a 5/3 chimeric serotype adenovirus armed with two human cytokines: TNF alpha and IL-2 where TILT-123 showed a 100% response rate in pre-clinical cancer models in vivo
Ref: Businesswire | Image: TILT Biotherapeutics
